Aprogen Biologics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	24,393	12,306	10,053	23,609	35,074
Short-Term Investments	-	-	-	390	75,000
Trading Asset Securities	27,240	26,013	-	75,075	14,861
Cash & Short-Term Investments	51,633	38,319	10,053	99,074	124,935
Cash Growth	34.75%	281.15%	-89.85%	-20.70%	-39.08%
Accounts Receivable	15,663	16,607	14,807	17,769	12,825
Other Receivables	5,344	1,682	1,828	4,256	8,259
Receivables	47,930	22,972	23,373	82,060	215,755
Inventory	51,601	52,286	48,128	52,313	10,420
Prepaid Expenses	726.67	895.05	2,490	558.14	10.67
Other Current Assets	2,638	729.2	812.78	6,604	2,354
Total Current Assets	154,529	115,200	84,857	240,608	353,474
Property, Plant & Equipment	322,533	321,458	318,212	323,773	18,857
Long-Term Investments	38,920	91,994	137,647	57,793	84,232
Other Intangible Assets	5,277	5,116	6,241	6,458	2,796
Long-Term Accounts Receivable	-	-	-	-	20,577
Long-Term Deferred Tax Assets	-	-	-	662.84	755.7
Other Long-Term Assets	24,936	3,676	3,793	10,099	9,229
Total Assets	586,993	590,984	589,397	684,140	614,621
Accounts Payable	3,073	1,996	1,333	3,809	652.59
Accrued Expenses	5,000	3,756	3,747	4,968	1,201
Short-Term Debt	167,612	103,630	129,360	134,263	2,162
Current Portion of Leases	2,509	2,191	1,360	345.5	199.49
Current Income Taxes Payable	-	-	-	4.18	273.93
Current Unearned Revenue	-	-	-	-	119.99
Other Current Liabilities	50,939	35,936	22,138	17,716	4,840
Total Current Liabilities	229,133	147,509	157,938	161,106	9,449
Long-Term Debt	40,000	32,000	32,000	-	-
Long-Term Leases	18,675	16,197	18,277	129.06	120
Pension & Post-Retirement Benefits	10,506	10,245	7,732	7,564	5,600
Long-Term Deferred Tax Liabilities	5,601	3,874	2,932	3,108	1,093
Other Long-Term Liabilities	5,510	2,470	1,827	1,823	1,178
Total Liabilities	309,426	212,294	220,705	173,730	17,440
Common Stock	99,204	99,204	332,877	292,877	199,288
Additional Paid-In Capital	704,331	704,331	358,030	335,850	327,715
Retained Earnings	-409,280	-239,199	-133,310	-8,085	-21,115
Treasury Stock	-4,485	-4,485	-4,463	-41.27	-41.27
Comprehensive Income & Other	-182,014	-181,360	-184,443	-194,079	2,092
Total Common Equity	207,757	378,491	368,691	426,521	507,939
Minority Interest	69,810	199.28	-	83,890	89,242
Shareholders' Equity	277,567	378,691	368,691	510,411	597,181
Total Liabilities & Equity	586,993	590,984	589,397	684,140	614,621
Total Debt	228,796	154,017	180,997	134,738	2,481
Net Cash (Debt)	-177,163	-115,698	-170,944	-35,664	122,454
Net Cash Growth	-	-	-	-	-39.41%
Net Cash Per Share	-13448.64	-13803.94	-40646.99	-13234.78	46085.02
Filing Date Shares Outstanding	13.18	13.17	4.38	3.9	2.66
Total Common Shares Outstanding	13.18	13.17	4.38	3.9	2.66
Working Capital	-74,604	-32,308	-73,081	79,502	344,025
Book Value Per Share	15764.78	28735.58	84108.18	109224.47	191160.18
Tangible Book Value	202,480	373,376	362,451	420,063	505,142
Tangible Book Value Per Share	15364.37	28347.19	82684.48	107570.66	190107.77
Land	38,461	29,664	25,156	28,315	9,313
Buildings	102,328	97,599	97,507	101,378	9,647
Machinery	225,657	179,320	118,620	145,738	10,258
Construction In Progress	30,975	64,463	108,996	90,433	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.